Alves Ana, Costa Paulo, Pinto Madalena, Ferreira Domingos, Correia-da-Silva Marta
UCIBIO, REQUIMTE, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal.
Laboratory of Pharmaceutical Technology, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal.
Molecules. 2021 May 5;26(9):2707. doi: 10.3390/molecules26092707.
Marine organisms are able to produce a plethora of small molecules with novel chemical structures and potent biological properties, being a fertile source for discovery of pharmacologically active compounds, already with several marine-derived agents approved as drugs. Glioma is classified by the WHO as the most common and aggressive form of tumor on CNS. Currently, Temozolomide is the only chemotherapeutic option approved by the FDA even though having some limitations. This review presents, for the first time, a comprehensive overview of marine compounds described as anti-glioma agents in the last decade. Nearly fifty compounds were compiled in this document and organized accordingly to their marine sources. Highlights on the mechanism of action and ADME properties were included. Some of these marine compounds could be promising leads for the discovery of new therapeutic alternatives for glioma treatment.
海洋生物能够产生大量具有新颖化学结构和强大生物学特性的小分子,是发现药理活性化合物的丰富来源,已有多种海洋来源的药物获批。世界卫生组织将胶质瘤归类为中枢神经系统中最常见且侵袭性最强的肿瘤形式。目前,替莫唑胺是美国食品药品监督管理局批准的唯一化疗药物,尽管存在一些局限性。本综述首次全面概述了过去十年中被描述为抗胶质瘤药物的海洋化合物。本文汇编了近五十种化合物,并根据其海洋来源进行了整理。还包括了作用机制和药物代谢动力学性质的要点。其中一些海洋化合物可能是发现胶质瘤治疗新替代疗法的有前景的先导物。